17,261 trials
Dementia With Lewy Bodies · REM Sleep Behavior Disorder · Parkinson's Disease Dementia
Primary: Change in the Frequency of REM Sleep Behavior Disorders (RBD) From Baseline to the End of the Treatment Period (28 Days) Based on a Clinical Evaluator. — -1.47; -0.26…
Hidradenitis Suppurativa
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 7 Participants
Colon Cancer · Rectal Cancer
Primary: Efficacy of Lymphoseek for Detection of Sentinel Nodes — 16 Participants
Heart Failure · Heart Failure Acute · Acute Cardiac Pulmonary Edema
Primary: Number of Participants With B-lines ≤ 15 at the Conclusion of ED AHF Management — 7; 10 Participants
Pain
Primary: Time-Weighted Sum of Pain Relief Rating and Pain Intensity Difference Scores From 0 to 8 Hours (SPRID 0-8) — 5.0; 30.8; 29.6; 31.7 units on a scale — p=<0.001
Hemophilia B
Primary: Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings — 0 Participants
Osteoarthritis, Knee
Primary: Change From Baseline to 4 Week Endpoint in Weekly Mean of Daily 24-Hour Average Pain Scores (APS) — -0.90; -1.20 units on a scale
Lupus Membranous Nephropathy
Primary: Percent Change in Urine Protein From Baseline (Day 1) to Week 16 — -2.8; -51.2 percent change
Atopic Dermatitis
Primary: Incidence of Treatment-Emergent Adverse Events — 29; 10; 1; 0 Participants
Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma · Multiple Myeloma
Primary: Numbers of Circulating CD34+ Cells on the First Day of Apheresis — 26; 30.7 Cells per microliter
Norovirus
Primary: Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by…
Homozygous Familial Hypercholesterolemia
Primary: Percentage Change From Day 1 to Day 90 in LDL-C — -12.26 percent change
Smoking Cessation
Primary: Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment — 26.62; 25.04; 47.10; 29.40…
Chronic Hepatitis B
Primary: Mean Change (Measured in log10 IU/mL) in Hepatitis B Surface Antigen (HBsAg) From Baseline at Week 24 — -0.163; -0.056; -0.146; -0.036 log10 IU/mL — p=0.227
Autism Spectrum Disorder · Autistic Disorder · Neurodevelopmental Disorder
Primary: Social Responsiveness Scale-2 (SRS-2) Total Score at Baseline — 75.6; 72.6 T-score — p=0.331